BIM bioMérieux S.A.
bioMérieux S.A. develops, manufactures, and markets in vitro diagnostic solutions for infectious diseases in France, Europe, Africa, the Middle East, North and South America, the Asia Pacific, and internationally. It operates through Clinical Applications and Industrial Applications segments. The company offers CHROMID RANGE, a chromogen culture media; air, surface, and water monitoring systems; BACT/ALERT VIRTUO, a blood sample culture system; BIOFIRE, a multiplex polymerase chain reaction system (PCR); BIOFIRE SPOTFIRE, a lowplex PCR point-of-care system; VITEK MS, a mass spectrometry system; VITEK 2, an automated identification and antimicrobial susceptibility testing (AST) system; API RANGE standardized ID strips; VITEK REVEAL, a rapid AST system; ETEST, a gradient method on culture media; BIOMERIEUX EPISEQ CS, a whole genome sequencing solution for epidemiologic monitoring; VIDAS, a specific marker of severe bacterial infections/sepsis; and Biomérieux vision suite, a software that provides information to support diagnosis and clinical decision making. It also provides culture media and associated instruments; ARGENE that provides PCR tests for diagnosing viral respiratory diseases; EMAG system and NUCLISENS extraction reagents for DNA and RNA extraction; GENE-UP and VERIFLOW for detection of microorganisms for the food industry; ETEST for manual measurement of minimum inhibitory concentration of antibiotic; API and RAPIDEC CARBA NP for identification of bacteria and manual antimicrobial susceptibility testing; BIOBALL for quantitative microbiological quality control; CHEMUNEX, a microbiology instrument; ENDONEXT for detection of endotoxins; TEMPO for fluorescence counting of bacteria; and Hybiome, a CLIA technology, as well as lab consultancy service and training modules. The company was formerly known as B-D Mérieux. The company was founded in 1963 and is headquartered in Marcy-l'Etoile, France. bioMérieux S.A. operates as a subsidiary of Institut Mérieux SA.…
Industry Peers
Diagnostics & ResearchKey Statistics
About bioMérieux (EPA: BIM)
›
bioMérieux (EPA: BIM) is listed on Euronext Paris, where its shares trade in EUR. It belongs to the Diagnostics & Research industry, part of the Healthcare sector, and reports about 14,562 employees.
The shares were at 91.30 EUR on 20 November 2026, down 16.0% over 52 weeks. Its 52-week range is 65.60 EUR to 116.10 EUR: the price is 21.4% below the high and 39.2% above the low.
At a market capitalisation of 10.77B EUR, it trades at 23.4 times trailing earnings and 19.5 times forward earnings. The median trailing P/E of its 18 largest Diagnostics & Research peers is 34.6, a discount of 32% for BIM. It pays a dividend yielding 1.08% (it pays out 25% of its earnings), against a median of 0.73% among the dividend payers in that peer group.
bioMérieux reports return on equity of 9.7%, an operating margin of 16.0% and revenue down 3.9% year over year.
It holds more cash than debt, a net cash position of 235.90M EUR. Its Piotroski F-score is 8 out of 9, a strong reading of its financial health. 13 analysts cover the stock, with an average rating of Hold; their mean price target of 89.04 EUR is 2.5% below the current price. The next earnings report is expected on 25 February 2027.